SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing significant volatility as investors react to the company's WWDC announcements, which included new AI integration features like a revamped Siri. While some in the community see the focus on privacy and ecosystem integration as a long-term catalyst, many traders are actively debating whether the news constitutes a classic 'sell the news' event or an underwhelming lack of innovation.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as a major data center lease with a hyperscaler adds significant contracted revenue to its multi-billion dollar backlog, driving strong community enthusiasm and expectations of a re-rating. While broader market volatility is causing price fluctuations, the community remains focused on the company's rapid infrastructure expansion, secured credit facilities, and long-term deal cadence as key indicators of sustained institutional demand.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position themselves ahead of imminent Phase 3 VELA data and a major presentation at the Goldman Sachs Healthcare Conference. The conversation is driven by intense speculation regarding a potential buyout, with many market participants viewing the company's recent commercial-ready manufacturing agreements and rare full-team conference attendance as tactical indicators of an approaching M&A catalyst.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is facing intense downward pressure and high volatility as investors react to rapid C-suite turnover, including the recent departure of its CRO and the appointment of a new CFO. While some in the community see the current price as an oversold buying opportunity with strong cash reserves, others are expressing significant frustration with management's performance and the lack of a major catalyst to break the stock's persistent downtrend.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors focus on its pivot toward AI infrastructure through the expansion of its massive Helios data center campus. The community is actively debating the company's valuation, the potential for new tenant announcements, and its transition from traditional crypto mining toward becoming a major player in the high-performance computing sector.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as investors weigh its potential to compete with major GLP-1 incumbents, particularly as the community analyzes emerging efficacy and tolerability data from industry rivals. Discussions are heavily focused on the upcoming Phase 1 maintenance trial readout, which is viewed as a pivotal catalyst for the stock's valuation.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve is trending as investors rally around its upcoming NYSE uplisting, viewing the move as a major institutional catalyst and a significant milestone for the US cannabis sector. The community is actively discussing the company's strong market position in Florida and the potential for increased institutional capital as it prepares to transition away from the OTC market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors rally behind positive Phase 3 clinical data for its next-generation obesity treatment, retatrutide, which demonstrates significant weight loss potential. The community is actively debating the stock's long-term competitive positioning against Novo Nordisk while monitoring institutional interest in the company's expanding vaccine and oncology pipelines.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors weigh potential federal rescheduling catalysts against new regulatory developments impacting the broader cannabis market. The community remains focused on the company's strong balance sheet, share repurchase initiatives, and its position as a top-tier operator relative to its sector peers.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is gaining momentum as investors weigh a major collaboration with Roche and ongoing clinical progress in protein degradation technology against recent analyst downgrades. The community is closely debating the deal's long-term value, potential for a short squeeze, and whether the current valuation fully reflects the company's robust drug development pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?

NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.

Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?

LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.

LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum. 

LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.

LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call 

Equity

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?

Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Key PointsDeep Track Capital acquired 168,066 shares of Structure Therapeutics last quarter; the estimated trade size was $11.50 million (based on quarterly average prices...

LLY Reports Third Phase III Win for Next-Generation Obesity Drug

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

Monashee Scales Back Its Bet on Structure Therapeutics

Key PointsMonashee sold 175,000 Structure Therapeutics shares; estimated trade size approximately $11.98 million based on the mean unadjusted close for the quarter...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Current Price	$37.77
Prev Close	$37.58
Open	$37.47
Dividend Yield	0.00%
50-Day Moving Average	$44.05
Beta	0.89
Avg. Volume	713,878.12
PE Ratio	-13.96

52-Week High	$94.90
52-Week Low	$15.80
Market Capitalization	$2.67B
EPS (Annual)	-$2.39
Price to Book	1.85
Revenue Per Employee	$0.00

GPCRStructure Therapeutics Inc - ADR

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News